Technical Analysis for HARP - Harpoon Therapeutics, Inc.

Grade Last Price % Change Price Change
B 20.51 3.85% 0.76
HARP closed up 3.85 percent on Thursday, April 22, 2021, on 88 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical HARP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
50 DMA Resistance Bearish 3.85%
Stochastic Reached Oversold Weakness 3.85%
Oversold Stochastic Weakness 3.85%
MACD Bearish Centerline Cross Bearish 8.35%
Hammer Candlestick Bullish 8.35%
Lizard Bullish Bullish Day Trade Setup 8.35%
Down 3 Days in a Row Weakness 8.35%
Older End-of-Day Signals for HARP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 13 hours ago
20 DMA Resistance about 15 hours ago
Rose Above 20 DMA about 16 hours ago
Rose Above 10 DMA about 16 hours ago
Up 3% about 16 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Diseases Immune System Immunotherapy Oncology Cancer Immunotherapy Prostate Cancer Small Cell Lung Cancer Ovarian Cancer Tumors Multiple Myeloma Proteins Resistant Prostate Cancer Treatment Of Ovarian Cancer Mesothelin Metastatic Castration Resistant Prostate Cancer Neuvenge

Is HARP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.235
52 Week Low 10.55
Average Volume 241,738
200-Day Moving Average 16.89
50-Day Moving Average 19.92
20-Day Moving Average 20.53
10-Day Moving Average 20.20
Average True Range 1.64
ADX 11.23
+DI 21.15
-DI 21.84
Chandelier Exit (Long, 3 ATRs ) 19.29
Chandelier Exit (Short, 3 ATRs ) 22.91
Upper Bollinger Band 22.75
Lower Bollinger Band 18.32
Percent B (%b) 0.5
BandWidth 21.59
MACD Line -0.05
MACD Signal Line 0.12
MACD Histogram -0.1719
Fundamentals Value
Market Cap 520.55 Million
Num Shares 25.4 Million
EPS -4.05
Price-to-Earnings (P/E) Ratio -5.07
Price-to-Sales 26.94
Price-to-Book 5.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.30
Resistance 3 (R3) 23.05 21.88 22.83
Resistance 2 (R2) 21.88 21.17 22.00 22.68
Resistance 1 (R1) 21.20 20.73 21.54 21.44 22.52
Pivot Point 20.02 20.02 20.19 20.14 20.02
Support 1 (S1) 19.34 19.31 19.68 19.58 18.50
Support 2 (S2) 18.16 18.87 18.29 18.34
Support 3 (S3) 17.48 18.16 18.19
Support 4 (S4) 17.72